Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Unadjusted risk factors associated with targeted meropenem prescription

From: Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital

 

Overall

(n = 457)

No meropenem

prescription

(n = 392)

Meropenem

prescription

(n = 65)

Univariate OR [95% CI]

P-value

Periods of study

    

 < 0.001

 Period #1 before EUCAST update

148 (32.4)

143 (96.6)

5 (3.4)

Ref

 

 Period #2 after EUCAST update w/o selective reporting

202 (44.2)

151 (74.8)

51 (25.3)

9.65 [3.74–24.89]

 

 Period #3 after EUCAST update with selective reporting

107 (23.4)

98 (91.6)

9 (8.4)

2.62 [0.85–8.07]

 

Age ≥ 65 years (%)

265 (57.9)

229 (58.4)

36 (55.4)

0.88 [0.52–1.49]

0.6

Female sex (%)

176 (38.5)

154 (39.3)

22 (33.9)

0.79 [0.45–1.45]

0.4

Immunosuppression (%)

78 (17.1)

62 (15.8)

16 (24.6)

1.73 [0.92–3.25]

0.08

History of ESBL infection/ colonisation (%)

10 (2.2)

6 (1.5)

4 (6.2)

4.21 [1.15–15.38]

0.03

Associated P. aeruginosa bacteraemia (%)

63 (13.8)

52 (13.3)

11 (16.9)

1.33 [0.65–2.71]

0.8

Sepsis or septic shock (%), missing = 2

91 (20.0)

64 (16.4)

27 (41.5)

3.61 [2.06–6.34]

 < 0.001

Rapid or ultimately fatal disease (%)

233 (50.9)

192 (48.9)

41 (63.1)

1.77 [1.03–3.05]

0.03

Healthcare associated infection (%)

256 (56.1)

210 (53.6)

46 (70.8)

2.09 [1.18–3.71]

0.01

Gram-negative rod coinfection (%)

117 (25.6)

93 (23.7)

24 (36.9)

1.88 [1.08–3.27]

0.026

IDs consultation after susceptibility testing (%)

240 (52.5)

204 (52.1)

36 (55.4)

1.14 [0.67–1.93]

0.6

Low respiratory tract infection (%)

176 (38.5)

139 (35.4)

37 (56.9)

2.40 [1.41–4.09]

0.001

  1. EUCAST European Committee on Antimicrobial Susceptibility Testing, ESBL Extended-Spectrum Beta Lactamase producing Enterobacteriales, IDs Infectious Diseases specialist